{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:04Z","timestamp":1791105664177,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":2533,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[1997,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Levodopa\u2010induced dyskinesias remain a major challenge in the therapeutic management of Parkinson's disease (PD). Their etiology is unknown although dysfunction of striatal opioid transmission has been implicated in experimental models of PD. To determine whether the opioid system is involved in human dyskinetic PD, we measured in vivo opioid receptor binding in PD patients with and without levodopa\u2010induced dyskinesias, using positron emission tomography (PET) and the opioid receptor ligand [\n                    <jats:sup>11<\/jats:sup>\n                    C]diprenorphine. Striatal and thalamic\/occipital uptake ratios were calculated using a region of interest (ROI) approach. In addition, we used statistical parametric mapping (SPM) and images reflecting the volume of distribution of [\n                    <jats:sup>11<\/jats:sup>\n                    C]diprenorphine to assess changes in cerebral receptor binding on a voxel\u2010by\u2010voxel basis. By using the ROI approach, we found significantly reduced striatal and thalamic opioid binding in dyskinetic, but not in nondyskinetic, PD patients. The SPM approach confirmed reduced availability in these areas and, in addition, showed decreased cingulate and increased prefrontal opioid receptor binding in the dyskinetic patients. Our findings confirm that altered opioid transmission is part of the pathophysiology of levodopa\u2010induced dyskinesias in PD and support further investigation into the role of opioid agents in the management of these involuntary movements.\n                  <\/jats:p>","DOI":"10.1002\/ana.410420508","type":"journal-article","created":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T10:09:40Z","timestamp":1104574180000},"page":"720-726","source":"Crossref","is-referenced-by-count":148,"title":["Alterations in opioid receptor binding in Parkinson's disease patients with levodopa\u2010induced dyskinesias"],"prefix":"10.1002","volume":"42","author":[{"given":"P.","family":"Piccini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Weeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.6.927"},{"key":"e_1_2_1_3_2","first-page":"275","article-title":"Differential effect of selective D1 and D2 dopamine receptor agonists on levodopa\u2010induced dyskinesia in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,4\u2010tetrahydropyridine\u2010exposed monkeys","volume":"267","author":"Blanchet P","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_4_2","first-page":"123","article-title":"PET studies of the striatal dopaminergic system in Parkinson's disease","volume":"45","author":"Piccini P","year":"1995","journal-title":"J Neural Transm"},{"key":"e_1_2_1_5_2","unstructured":"TurjanskiN LeesAJ BrooksDJ. In vivo studies on striatal dopamine D1and D2site binding in l\u2010dopa treated Parkinson's disease patients with or without dyskinesia.Neurology(in press)"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(85)90272-6"},{"key":"e_1_2_1_7_2","first-page":"1370","article-title":"Enkephalinergic and GABAergic modulation of motor activity in the ventral pallidum","volume":"252","author":"Austin MC","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90667-K"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90295-F"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(95)00084-6"},{"key":"e_1_2_1_11_2","first-page":"518","article-title":"An automated system based on solid phase extraction and HPLC for the routine determination in plasma of unchanged [11C]deprenyl, [11C]diprenorphine, [11C]flumazenil, [11C]raclopride and [11C]Schering 22390","volume":"32","author":"Luthra SK","year":"1993","journal-title":"J Label Comp Radiopharm"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1109\/23.12819"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(94)90002-7"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1993.5"},{"key":"e_1_2_1_15_2","first-page":"101","volume-title":"Quantification of brain function. Tracer kinetic and image analysis in brain PET","author":"Cunningham VJ","year":"1993"},{"key":"e_1_2_1_16_2","first-page":"289","volume-title":"Quantification of brain function","author":"Tadokoro M","year":"1993"},{"key":"e_1_2_1_17_2","unstructured":"WeeksRA CunninghamVJ PicciniP et al. [11C]Diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping.J Cereb Blood Flow Metab(in press)"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.460020402"},{"key":"e_1_2_1_19_2","unstructured":"RinneUK RinneJK RinneJO et al. Brain enkephalin receptors in Parkinson's disease.J Neural Transm1983; (suppl 19):163\u2013171"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(87)91321-7"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)90061-2"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)00606-6"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(90)90020-E"},{"issue":"1","key":"e_1_2_1_24_2","first-page":"61","article-title":"Opioid peptide involvement in l\u2010dopa\u2010induced dyskinesias: molecular and behavioural studies following long\u2010term treatment in the 6\u2010OHDA\u2010lesioned rat model of Parkinson's disease","volume":"11","author":"Henry B","year":"1996","journal-title":"Mov Disord"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(91)90526-H"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050203"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(84)90196-4"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(85)90102-7"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/271178a0"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1994.1007"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)00358-W"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00385-X"},{"key":"e_1_2_1_33_2","first-page":"1","article-title":"Potential of opioid antagonists in the treatment of levodopa\u2010induced dyskinesias in Parkinson's disease","volume":"9","author":"Henry B","year":"1966","journal-title":"Drugs Ageing"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(85)90379-6"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/118.4.951"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(95)02014-4"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1995.1069"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/89.6.401"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410300105"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080405"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1978.00500360034006"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510140054014"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.1.118a"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090410"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.410420508","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.410420508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T19:15:20Z","timestamp":1698434120000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.410420508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,11]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1997,11]]}},"alternative-id":["10.1002\/ana.410420508"],"URL":"https:\/\/doi.org\/10.1002\/ana.410420508","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,11]]}}}